Physician profile
Rebecca Bowman
NPI 1376966838
$20,242.83
in general payments reported to CMS, 2019-2025
40 companies · $5,340 in 2025
The $5,340 reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,376 · 2022: $3,700 · 2023: $3,365 · 2024: $4,461 · 2025: $5,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,009.88 |
| Education | $156.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,045.24 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,655.85 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $2,381.69 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $1,016.61 | 2022-2025 | |
| Janssen Biotech, INC. | $814.31 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $767.18 | 2021-2025 | Livdelzi, Epclusa |
| Ardelyx, INC. | $644.33 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $535.24 | 2021-2025 | Ocaliva |
| Lilly USA, LLC | $520.18 | 2024-2025 | Omvoh |
| Celgene Corporation | $500.13 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $434.01 | 2021-2023 | |
| Redhill Biopharma INC. | $417.64 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $406.18 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $380.49 | 2021-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $356.34 | 2021-2025 | Injectafer |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $318.48 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $300.31 | 2024-2025 | Vowst, Zenpep |
| Medtronic, INC. | $295.55 | 2023-2025 | Interstim |
| Ipsen Biopharmaceuticals, INC | $251.10 | 2024-2025 | Iqirvo, Bylvay |
| Novo Nordisk INC | $187.37 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $162.40 | 2021-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $120.44 | 2022 | |
| Fresenius Kabi USA, LLC | $111.41 | 2023-2024 | Idacio |
| Vivus LLC | $81.46 | 2021-2025 | Qsymia |
| Evoke Pharma, INC. | $73.09 | 2022-2025 | |
| Madrigal Pharmaceuticals | $58.89 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $57.82 | 2023 | Dupixent |
| Celltrion USA INC. | $51.98 | 2024 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.74 | 2024 | Cyltezo |
| Amgen INC. | $35.56 | 2023-2025 | Uplizna, Amjevita |
| Exact Sciences Corporation | $34.62 | 2023-2025 | The Cologuard Plus Collection Kit |
| Mylan Institutional INC. | $31.10 | 2023 | Hulio |
| Braintree Laboratories, INC. | $27.91 | 2021-2024 | Suflave, Sutab |
| Mirum Pharmaceuticals, INC. | $26.04 | 2023 | Livmarli |
| Axonics, INC. | $20.00 | 2021 | |
| Biocon Biologics INC | $18.51 | 2024 | Hulio |
| Csl Behring | $16.07 | 2021 | |
| Alfasigma USA, INC. | $15.17 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.91 | 2023 | Rebyota |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.